Hepatitis Therapeutics Market: Public Concerns of Morbidity and Mortality and Burden on Healthcare Systems of Hepatitis steers Growth, Market projected to expand at 2.3% CAGR from 2018 - 2026, TMR
- Rising penetration of global players to make Asia Pacific prominent region in the near future
ALBANY, N.Y., March 16, 2021 /PRNewswire/ Most commonly caused by a group of viruses known as the hepatitis viruses, hepatitis is an inflammation of the liver that can cause a number of health problems and can even lead to death. There are five main strains of the hepatitis virus, namely type A, B, C, D, and E. While all strains of hepatitis viruses causes liver disease, each type of virus strain is related to different severity of the illness. In particular, type B and type C are related to chronic diseases of the liver, cancer and viral hepatitis-related fatalities. According to statistics published by the World Health Organization, hepatitis B and/or C is prevalent in approximately 325 mil
Empress Royalty Corp.: Empress Announces C$12 Million Bought Deal Public Offering
VANCOUVER, BC / ACCESSWIRE / March 16, 2021 / Empress Royalty Corp. (TSXV:EMPR)(OTCQB:EMPYF) (
Empress or the
Company ) is pleased to announce that it has entered into an agreement with Red Cloud Securities Inc. and Canaccord Genuity Corp. to act as co-lead underwriters on behalf of a syndicate of underwriters (collectively, the
Underwriters ) pursuant to which the Underwriters shall purchase for resale 24,000,000 units of the Company (the
Units ) at a price of C$0.50 per Unit (the
Offering Price ) on a bought deal basis for gross proceeds of C$12,000,000 (the
Offering ). Each Unit shall be comprised of one common share in the capital of the Company (each a